key: cord-0744077-g5opwwf0
authors: Soltani, Saber; Zandi, Milad
title: miR-200c-3p upregulation and ACE2 downregulation via bacterial LPS and LTA as nteresting aspects for COVID-19 treatment and immunity
date: 2021-05-03
journal: Mol Biol Rep
DOI: 10.1007/s11033-021-06378-x
sha: ca89976097cc8e807e93a0c956e195a01fd732cd
doc_id: 744077
cord_uid: g5opwwf0

nan

According to evidence, LPS activates NF-κB via TLR4 and LTA via TLR2 [7] . On the other hand, activation of the NF-κB pathway increases the expression of miR-200c-3p, which is an important factor in ARDS [7] . Increased expression of miR-200c-3p has been observed to decrease ACE2 expression [7] . It should be noted that low expression of ACE2 in the lungs and the upper respiratory tract in some COVID-19 cases may be associated with a reduction in disease severity [9] . Therefore, it is hypothesized that bacterial LPS and LTA can reduce the expression of ACE2 in the lungs of COVID-19 patients through upregulation of miR-200c-3p.

Murine models of SARS-CoV have confirmed that the virus may stimulate TNF-α and IL-6 through the NF-κB pathway [10] . Shaath et al. reported, NF-κB was activated in B.A.L. cells of severe COVID-19 [11] . This issue would clarify the high levels of cytokine responses, leading to inflammation and cytokines storm in COVID-19 patients. The cytokines storm in COVID-19 could result in ARDS and multi-organ dysfunction. This aspect could help in the design of effective vaccine and therapeutic approaches [10, 12] . Respiratory bacterial can also develop NF-κB activation, which induces a pro-inflammatory response in epithelial cells [13, 14] . The human microbiota can be altered after SARS-CoV-2 infection [15] . It is a hypothesis that these microbiota changes can illustrate the cytokines storm progression in COVID-19. Therapy using NF-κB inhibitor drugs leads to decreased inflammation and lung injury in SARS-CoV-infection models [16] . The differential miRNA expression in COVID-19 patients may regulate the inflammatory responses during infection [17] . Also, Some miR-NAs can target ACE2 [18] . The "microRNA targeting" as anti-inflammatory agents should be carefully considered. It is well known that microRNAs are strongly involved in cytokines and chemokines expression, leading to cytokines storm in COVID-19 [19] .

In conclusion, the composition of bacterial respiratory microbiota can be an indicator of COVID-19 severity. Future clinical trials are needed to investigate the role of probiotics containing LPA and LTA in affect on COVID-19 symptoms by upregulation miR-200c-3p levels and downregulation ACE2 levels in COVID-19 patients. Future studies in the gene therapy field could also directly investigate the role of miR-200c-3p as a biomarker in reducing ACE2 expression and COVID-19 severity to provide immunity against SARS-CoV-2.

Authors contribution SS: literature search, writing, design, editing, and final proof. MZ: Editing and final proof.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor

Impact of the respiratory microbiome on host responses to respiratory viral infection

The role of the bacterial microbiome in lung disease

Lung microbiome and coronavirus disease 2019 (COVID-19): possible link and implications

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

miRNA-200c-3p is crucial in acute respiratory distress syndrome

microRNAs in viral acute respiratory infections: immune regulation, biomarkers, therapy, and vaccines

Differential expression of ACE2 in the respiratory tracts and its relationship to COVID-19 pathogenesis

Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway

Single-cell transcriptome analysis highlights a role for neutrophils and inflammatory macrophages in the pathogenesis of severe COVID-19

The cytokine storm of COVID-19: a spotlight on prevention and protection

Unraveling the interconnection patterns across lung microbiome, respiratory diseases, and COVID-19

Induction of NF-kap-paB nuclear translocation in human respiratory epithelial cells by group A streptococci

The role of bacterial and fungal human respiratory microbiota in COVID-19 patients

NF-κB as a potential therapeutic target in microbial diseases

Differential microRNA expression in the peripheral blood from human patients with COVID-19

MicroRNA mimics or inhibitors as antiviral therapeutic approaches against COVID-19

Tackling the COVID-19 "cytokine storm" with microRNA mimics directly targeting the 3'UTR of pro-inflammatory mRNAs

The authors have no conflict of interest to declare.